Clopidogrel and proton pump inhibitors: Influence of pharmacological interactions on clinical outcomes and mechanistic explanations

Udaya S. Tantry, Dean J. Kereiakes, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Dual antiplatelet therapy with aspirin and clopidogrel is associated with a significant reduction in vascular ischemic events; however, gastrointestinal bleeding events are a major concern in high-risk and older patients. Clinical practice guidelines recommend combination therapy with proton pump inhibitors (PPI) and dual antiplatelet therapy to attenuate gastrointestinal bleeding risk. In addition, high on-treatment platelet reactivity has been associated with recurrent ischemic events. Whether or not the pharmacological interaction between clopidogrel and PPI, which results in diminished antiplatelet effect, adversely influences clinical efficacy is highly controversial and the subject of debate. Based on largely anecdotal post-hoc analyses, the U.S. Federal Drug Administration's and European Medicines Agency's recommendations discourage PPI use (particularly omeprazole) in patients treated with clopidogrel. However, many American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions experts do not support change in clinical practice guidelines recommendations without adequately powered, prospective, randomized clinical trial data.

Original languageEnglish (US)
Pages (from-to)365-380
Number of pages16
JournalJACC: Cardiovascular Interventions
Volume4
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

clopidogrel
Proton Pump Inhibitors
Pharmacology
Practice Guidelines
Hemorrhage
Omeprazole
Therapeutics
Aspirin
Blood Vessels
Blood Platelets
Randomized Controlled Trials
Pharmaceutical Preparations

Keywords

  • bleeding
  • clopidogrel
  • cytochromes
  • drug-drug interactions
  • omeprazole
  • platelet reactivity
  • proton pump inhibitors
  • single nucleotide polymorphisms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clopidogrel and proton pump inhibitors : Influence of pharmacological interactions on clinical outcomes and mechanistic explanations. / Tantry, Udaya S.; Kereiakes, Dean J.; Gurbel, Paul A.

In: JACC: Cardiovascular Interventions, Vol. 4, No. 4, 04.2011, p. 365-380.

Research output: Contribution to journalArticle

@article{7cb59fd0fa794f2997c5d2b5340cfb23,
title = "Clopidogrel and proton pump inhibitors: Influence of pharmacological interactions on clinical outcomes and mechanistic explanations",
abstract = "Dual antiplatelet therapy with aspirin and clopidogrel is associated with a significant reduction in vascular ischemic events; however, gastrointestinal bleeding events are a major concern in high-risk and older patients. Clinical practice guidelines recommend combination therapy with proton pump inhibitors (PPI) and dual antiplatelet therapy to attenuate gastrointestinal bleeding risk. In addition, high on-treatment platelet reactivity has been associated with recurrent ischemic events. Whether or not the pharmacological interaction between clopidogrel and PPI, which results in diminished antiplatelet effect, adversely influences clinical efficacy is highly controversial and the subject of debate. Based on largely anecdotal post-hoc analyses, the U.S. Federal Drug Administration's and European Medicines Agency's recommendations discourage PPI use (particularly omeprazole) in patients treated with clopidogrel. However, many American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions experts do not support change in clinical practice guidelines recommendations without adequately powered, prospective, randomized clinical trial data.",
keywords = "bleeding, clopidogrel, cytochromes, drug-drug interactions, omeprazole, platelet reactivity, proton pump inhibitors, single nucleotide polymorphisms",
author = "Tantry, {Udaya S.} and Kereiakes, {Dean J.} and Gurbel, {Paul A.}",
year = "2011",
month = "4",
doi = "10.1016/j.jcin.2010.12.009",
language = "English (US)",
volume = "4",
pages = "365--380",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Clopidogrel and proton pump inhibitors

T2 - Influence of pharmacological interactions on clinical outcomes and mechanistic explanations

AU - Tantry, Udaya S.

AU - Kereiakes, Dean J.

AU - Gurbel, Paul A.

PY - 2011/4

Y1 - 2011/4

N2 - Dual antiplatelet therapy with aspirin and clopidogrel is associated with a significant reduction in vascular ischemic events; however, gastrointestinal bleeding events are a major concern in high-risk and older patients. Clinical practice guidelines recommend combination therapy with proton pump inhibitors (PPI) and dual antiplatelet therapy to attenuate gastrointestinal bleeding risk. In addition, high on-treatment platelet reactivity has been associated with recurrent ischemic events. Whether or not the pharmacological interaction between clopidogrel and PPI, which results in diminished antiplatelet effect, adversely influences clinical efficacy is highly controversial and the subject of debate. Based on largely anecdotal post-hoc analyses, the U.S. Federal Drug Administration's and European Medicines Agency's recommendations discourage PPI use (particularly omeprazole) in patients treated with clopidogrel. However, many American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions experts do not support change in clinical practice guidelines recommendations without adequately powered, prospective, randomized clinical trial data.

AB - Dual antiplatelet therapy with aspirin and clopidogrel is associated with a significant reduction in vascular ischemic events; however, gastrointestinal bleeding events are a major concern in high-risk and older patients. Clinical practice guidelines recommend combination therapy with proton pump inhibitors (PPI) and dual antiplatelet therapy to attenuate gastrointestinal bleeding risk. In addition, high on-treatment platelet reactivity has been associated with recurrent ischemic events. Whether or not the pharmacological interaction between clopidogrel and PPI, which results in diminished antiplatelet effect, adversely influences clinical efficacy is highly controversial and the subject of debate. Based on largely anecdotal post-hoc analyses, the U.S. Federal Drug Administration's and European Medicines Agency's recommendations discourage PPI use (particularly omeprazole) in patients treated with clopidogrel. However, many American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions experts do not support change in clinical practice guidelines recommendations without adequately powered, prospective, randomized clinical trial data.

KW - bleeding

KW - clopidogrel

KW - cytochromes

KW - drug-drug interactions

KW - omeprazole

KW - platelet reactivity

KW - proton pump inhibitors

KW - single nucleotide polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=79955118104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955118104&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2010.12.009

DO - 10.1016/j.jcin.2010.12.009

M3 - Article

C2 - 21511216

AN - SCOPUS:79955118104

VL - 4

SP - 365

EP - 380

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 4

ER -